A Universal Multi-Omic Engine for OEM Partners

Precision health and clinical AI systems are no longer limited by algorithms—they are limited by data. Most AI models are trained on sparse, single-omic, or proxy measurements that fail to capture the true biological state of a patient in real time.

Guanine provides the missing diagnostic data layer for precision health AI: a single electrochemical platform capable of generating high-plex, quantitative, multi-omic measurements—including proteins, nucleic acids, metabolites, redox states, and cellular responses—from the same sample.

By unifying these signals into clinically aligned consistent outputs, Guanine enables AI systems to move beyond static risk scores toward dynamic, biologically grounded decision models.

• High-plex, multi-omic data from a single assay
• Quantitative signals suitable for model training and inference
• Longitudinal measurement without assay redesign
• Consistent data generation across POC, lab, and high-throughput formats
• Lower cost per feature, enabling population-scale deployment

Guanine transforms diagnostics from a bottleneck into a scalable sensing layer for precision health AI—supporting earlier detection, better stratification, and continuously learning care pathways.

Drug development increasingly depends on diagnostics—not only to select patients, but to understand therapeutic response across development and clinical use. Yet today’s pharmaceutical diagnostics remain slow, narrow, and fragmented, limiting insight and increasing trial complexity.

Guanine enables a new class of pharmaceutical diagnostics by delivering integrated, multi-omic measurement and functional assessment from a single platform—supporting biomarker discovery, patient stratification, and therapy monitoring across the drug lifecycle.

Measure multiple biomarker classes simultaneously from small sample volumes to reduce assay burden and improve statistical power.

• Multi-omic biomarker panels on one platform
• Longitudinal monitoring without platform changes
• Earlier pharmacodynamic and response signals
• Improved subgroup identification and trial efficiency

Develop and evolve high-plex CDx panels aligned with modern targeted and combination therapies—without changing platforms.

• High-plex panels matched to complex mechanisms of action
• Scalable expansion as biomarkers evolve
• Single platform across development, validation, and deployment

Go beyond concentration-only monitoring by assessing therapeutic effect alongside exposure.

• Real-time response indicators
• Support for narrow therapeutic index drugs
• Potential integration of exposure, response, and resistance markers

Across trials, CDx, and TDM, Guanine provides pharmaceutical partners with a unified diagnostic engine—reducing complexity, accelerating development timelines, and enabling data-driven precision therapy at scale.